AKIGAI was founded with one purpose: to accelerate the development of EGFR inhibitors for the treatment of neuropathic pain, so that safe and effective options may become broadly available.
At present, our medicines are not yet approved or reimbursed for these conditions. Still, we are convinced that an effective treatment can be developed. Clinical trials are being planned, and when ready, we will share details here, including who can participate, trial centers, contact information, and timelines.
We are deeply moved by the suffering faced by people living with neuropathic pain. The relief we have already witnessed in some patients is both a motivation and a responsibility for us to continue this work.
We will update it as our work progresses, as we move toward our mission: to bring an effective solution for treating CRPS and neuropathic pain to as many patients as possible, as quickly as possible.